Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.7252W HIGH $24.50
Volume
394.80 K
Value Traded
5.84 M
Short % Float
14.97%
Days to Cover
7.3
-13.15%Week
-34.12%1 Month
-37.15%3 Month
-27.7%6 Month
-9.4%5 Year
-9.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
837.63 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
320.31 M
Total Shares
55.62 M
Float Shares
31.50 M
Insiders
43.37%
Institutions
43.73%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AKTS Catalyst Timeline
Dated clinical, regulatory and corporate events for Aktis Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aktis Oncology, Inc.
15Total events
5Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 6
●Trial InitiationAKY-2519Trial
Aktis initiates Phase 1b BActinium-2 trial of AKY-2519 in NSCLC and other B7-H3 expressing tumors
non-small cell lung cancer (NSCLC) and other B7-H3 expressing solid tumorssource ↗
▲Trial InitiationAKY-2519Trial
Initiated Phase 1b trial of AKY-2519 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Oral PresentationAKY-2519Presentation
First-in-human clinical imaging and dosimetry data for AKY-2519 presented at ASCO Annual Meeting
mCRPC, NSCLC and other B7-H3 expressing tumor typessource ↗
●Trial InitiationAKY-2519Trial
Aktis initiated Phase 1b BActinium-1 trial of AKY-2519 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Trial InitiationAKY-2519Trial
Initiated Phase 1b trial of AKY-2519 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
Past FDA Catalysts and PDUFA Decisions
How AKTS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 46%
Micro Cap(rank 302 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ac-AKY-2519 Small moleculeNCT07581184 | Castration Resistant Metastatic Prostate Cancer | Phase 1 | RECRUITING | 138 | Jun 1, 2032 | ||||||
| Ac-AKY-1189 Small moleculeNCT07020117 | Urothelial Carcinoma Bladder | Phase 1 | RECRUITING | 150 | Jun 1, 2032 |
Clinical Trial Results
Readouts, endpoints and source filings for every AKTS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AKY-2519 | metastatic castration-resistant prostate cancer (mCRPC) | Phase 1b | 2026-08-13 | Data demonstrated robust tumor uptake and retention of AKY-2519 with limited normal tissue exposure, suggesting the potential for a wide therapeutic window and differentiated profile compared to approved radiopharmaceuticals. Imaging and dosimetry with AKY-2519 were generally well tolerated, with no reported adverse events or infusion-related reactions.Read More | Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Czibere AkosOfficer (Chief Medical Officer) | Option | 12,500 12,500 held | $4.95 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AKTS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BIOIMPACT CAPITAL LLC | 9.5 % (41.8 %) | 155.86 M | 4.84 M |
AKTS Institutional Ownership Trends
AKTS Short Interest
Shares sold short, counted twice a month.
14.97%
Short % of Float
of tradable shares sold short
4.7M
Shares Sold Short
+45.0% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
645.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AKTS ranks across every disease it competes in
Competitive Position is a premium feature
See how AKTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAKTS News
AKTSAktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Aktis Oncology has launched the Phase 1b BActinium-2 clinical trial for AKY-2519, targeting non-small cell lung cancer and other B7-H3 expressing tumors. This trial follows the ongoing BActinium-1 trial in metastatic castration-resistant prostate cancer. Preliminary data from both trials is anticipated, with the potential for AKY-2519 to offer a new therapeutic option in oncology.
Read more →AKTSAktis Oncology to Present at Upcoming September Investor Conferences
Aktis Oncology, a clinical-stage oncology company, announced that CEO Matthew Roden will present at two investor conferences in September 2026. The conferences include the Morgan Stanley 24th Annual Global Healthcare Conference and the Oppenheimer 4th Annual Targeted Radiopharmaceutical Therapies in Oncology Summit. Aktis is focused on expanding targeted radiopharmaceuticals to address large patient populations.
Read more →AKTSAktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Aktis Oncology reported positive financial results and business highlights for Q2 2026, emphasizing progress in their clinical pipeline. The company is advancing multiple Phase 1b trials for AKY-2519 and AKY-1189, with promising imaging data presented at ASCO. Their cash position is strong, expected to support operations through 2029, despite an increase in net loss due to higher expenses.
Read more →AKTSAktis Oncology to Present at the Jefferies Global Healthcare Conference
Aktis Oncology, a clinical-stage oncology company, will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Matthew Roden will discuss the company's innovative miniprotein radioconjugate platform, which aims to address unmet needs in cancer treatment. The event will be accessible via a live webcast, with an archived replay available for 90 days.
Read more →AKTSAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology reported promising first-in-human clinical imaging and dosimetry data for AKY-2519, a radioconjugate targeting B7-H3 expressing tumors. The data indicated robust tumor uptake and minimal exposure to normal tissues, supporting the advancement of a broad clinical development program. Results will be presented at the 2026 ASCO Annual Meeting, with further trials expected to begin later this year.
Read more →AKTSAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology reported its financial results for Q1 2026, highlighting the initiation of a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC). The company also announced a second trial strategy for AKY-2519 and ongoing enrollment for AKY-1189. Financially, Aktis has a strong cash position, but it also noted an increase in net loss and R&D expenses.
Read more →AKTSAktis Oncology to Present at the BofA Securities Health Care Conference
Aktis Oncology will present at the BofA Securities Health Care Conference on May 13, 2026. CEO Matthew Roden will discuss the company's innovative miniprotein radioconjugate platform, which targets various solid tumors. Aktis aims to address unmet patient needs through its advanced pipeline, including programs targeting Nectin-4 and B7-H3.
Read more →AKTSAktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, targeting metastatic castration-resistant prostate cancer (mCRPC). This trial is part of a broader strategy that includes a second basket trial for other solid tumors expressing B7-H3. Preliminary data from the mCRPC trial is expected in 2027, highlighting the company's commitment to addressing significant unmet needs in cancer treatment.
Read more →AKTSAktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Aktis Oncology announced that clinical imaging and dosimetry data for AKY-2519 will be presented at the 2026 ASCO Annual Meeting. The data will enhance understanding of AKY-2519's biodistribution in patients with B7-H3 expressing solid tumors. A Phase 1b clinical trial for AKY-2519 is set to begin in mid-2026.
Read more →AKTSAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Aktis Oncology has appointed Glenn Gormley, MD, PhD, to its Board of Directors and as co-chair of the Science and Technology Committee. Gormley brings extensive experience in biopharmaceutical leadership and oncology innovation, having previously led significant developments in antibody drug conjugates. His appointment coincides with the planned departure of two board members, marking a strategic shift as Aktis advances its targeted radiopharmaceuticals pipeline.
Read more →AKTS▲ +8.9%on this news
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Aktis Oncology has received FDA clearance for its Investigational New Drug applications for AKY-2519, a miniprotein radioconjugate targeting B7-H3 in solid tumors. The company anticipates starting a Phase 1b clinical trial for AKY-2519 in mid-2026, alongside ongoing trials for its lead candidate, AKY-1189. Aktis reported a net loss of $63.7 million for 2025 but maintains a strong cash position to support its operations.
Read more →AKTSAktis Oncology to Present at Upcoming March 2026 Investor Conferences
Aktis Oncology, Inc. announced that its CEO, Matthew Roden, will present at two investor conferences in March 2026. The presentations will highlight the company's advancements in targeted radiopharmaceuticals, particularly their proprietary miniprotein radioconjugate platform. This platform aims to enhance cancer treatment efficacy while minimizing side effects. The conferences will take place in Boston and Miami.
Read more →AKTSAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
Aktis Oncology has announced that the FDA granted Fast Track designation to its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer. This designation allows for expedited development and review processes, addressing a significant unmet medical need. AKY-1189 utilizes a miniprotein radioconjugate platform to target Nectin-4 expressing tumors, with a Phase 1b clinical trial currently underway.
Read more →About Aktis Oncology, Inc.
Headquarters17 DRYDOCK AVENUE, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next AKTS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime